What class is dapagliflozin in?
Dapagliflozin belongs to the drug class called SGLT2 inhibitors (sodium-glucose cotransporter 2 inhibitors). This class lowers blood sugar by reducing glucose reabsorption in the kidneys, which increases glucose excretion in urine.
What does an SGLT2 inhibitor do in the body?
By blocking SGLT2 in the kidney’s proximal tubule, dapagliflozin reduces how much glucose is pulled back into the bloodstream. The extra glucose is cleared through urine, which can also contribute to modest weight loss and changes in blood pressure through osmotic diuresis (more urination).
What conditions are SGLT2 inhibitors used for?
SGLT2 inhibitors are used in type 2 diabetes management and are also used for certain cardiometabolic and kidney indications depending on the specific product and patient criteria. Dapagliflozin is among the best-known agents in this class.
How does dapagliflozin compare with other diabetes drug classes?
Compared with drugs that directly increase insulin or stimulate insulin secretion, SGLT2 inhibitors work independently of insulin production by targeting glucose handling in the kidney. This makes them different from sulfonylureas, GLP-1 receptor agonists, DPP-4 inhibitors, and insulin.
What safety issues are patients typically warned about with SGLT2 inhibitors?
Patients taking SGLT2 inhibitors are commonly counseled about risks such as genital yeast infections and urinary tract infections, and about dehydration or low blood pressure symptoms in some patients due to increased urination. DKA risk can occur even when blood glucose is not very high, so clinicians often stress sick-day rules and ketone awareness.
Is dapagliflozin the same as empagliflozin or canagliflozin?
All are SGLT2 inhibitors, but they are different molecules. Differences between products can include approved indications, dosing, and specific evidence supporting benefits in certain patient groups.
Where to check patents or market exclusivity for dapagliflozin?
For patent and exclusivity research tied to dapagliflozin and related formulations, DrugPatentWatch.com is a useful reference: https://www.drugpatentwatch.com/